U.S. Court of Appeals Affirms Validity of Lilly's Strattera Patent

Eli Lilly and Company LLY today announced that the U.S. Court of Appeals for the Federal Circuit has overturned a prior ruling by the U.S. District Court for the District of New Jersey and has upheld the validity of the company's method-of-use patent on Strattera® (atomoxetine). In the case of Eli Lilly and Company v. Actavis Elizabeth LLC, et al, the court ruled in favor of Lilly, upholding the method-of-use patent which provides protection for Strattera through May of 2017.